



Fall 2019 Meeting Plenary II Disclosure Information

Charles Blanke, MD, FACP, FASCO: None

Don Dizon, MD, FACP, FASCO: None

Mark Lewis, MD: None

Olufunmilayo Olopade, MD, FACP: Co-founder and stockholder of CancerIQ; Scientific advisory board member of Tempus

Bonnie Spring, PhD: None

Plenary II Agenda

- News & Accomplishments
- Farewells and Welcomes
- Young Investigator Training Course
- SEED Award Winner
- Plenary Speakers:
 - Don Dizon, MD
 - Mark Lewis, MD
 - Bonnie Spring, PhD
 - **Harry E. Hynes Memorial Lecture:** Olofunmilayo Olopade, MD

News & Accomplishments



Francis S. Collins @NIHDirector · Sep 18

New #NIH-funded study finds that ~half of phase 3 #clinicaltrials by @theNCI's SWOG Cancer Research Network were associated w/ advancing patient standard of care via clinical care guidelines or drug approvals.

45%

OF 182 PHASE 3 CLINICAL TRIALS

BETWEEN 1980 AND 2017

**INFLUENCED GUIDELINE CARE
OR NEW DRUG APPROVALS**

Study quantifies impact of NIH-sponsored trials on clinical cancer
Researchers found trials add value regardless of whether findings were
positive or negative.

nih.gov

2

26

61



Dr. Doug Lowy @NCIDrDougLowy · Sep 18

This study from @SWOG provides evidence for what we would expect to see: cancer clinical trials conducted in @theNCI's National Clinical Trials Network play a critical role in identifying effective treatment options for patients.



NCI Media Relations @NCIMedia · Sep 18

A new study shows nearly half of phase 3 cancer clinical trials carried out by @theNCI -sponsored SWOG Cancer Research Network, one of 5 groups in NCI's National Clinical Trials Network, were associated with clinical care guidelines or new drug approvals bit.ly/2LAgYEi

OF 182 PHASE 3 CLINICAL TRIALS

BETWEEN 1980 AND 2017

**INFLUENCED GUIDELINE CARE
OR NEW DRUG APPROVALS**

Source: Unger JM et al. JAMA Netw Open. doi:10.1001/jamanetworkopen.2019.10593



***Industry-run \$1.73 billion**

Our NCI Budgets

- Good to excellent news
- NCTN, NCORP, and stats budgets all increased

NCI Funding

March 2019-2025

NCTN

Category	Grant Year 5 PREVIOUS GRANT CYCLE	Grant Year 6 NEW GRANT CYCLE	Difference
Total Cost	\$11,571,699	\$12,139,981	+568,282

NCORP

Category	Grant Year 5 PREVIOUS GRANT CYCLE	Grant Year 6 NEW GRANT CYCLE	Difference
Total Cost	\$5,961,114	\$6,737,472	+776,358

NCTN Site Payments

Accrual Type	Main Member/Affiliate & Standard NCORP Rate	LAPS & High-Performing NCORP Rate
Screening on Study*	\$600 (Variable)	\$600 (Variable)
Treatment Intervention Non-IND study	\$2,700	\$4,300
Treatment Intervention IND study (Non-CTEP)	\$3,000	\$4,600
Treatment Intervention IND study (CTEP)	\$3,600	\$5,200
Imaging (base accrual)	\$1,200	\$1,200
Biospecimen Collections	Variable	Variable
	\$500/pt/trial	\$500/pt/trial

NCORP Site Payments

Accrual Type	Main member/Affiliate, LAPS & Standard NCORP Rate	High-Performing NCORP Rate
Screening on Study*	Variable	Variable
Cancer Control/Prevention/ QOL Intervention	\$3,000	\$5,000
Biospecimen Collections	Variable	Variable

ImmunoMATCH

 **NATIONAL CANCER INSTITUTE**

1-800-4-CANCER Live Chat Publications Dictionary

ABOUT CANCER CANCER TYPES **RESEARCH** GRANTS & TRAINING NEWS & EVENTS ABOUT NCI search

Home > Research > Research Areas > Cancer Treatment Research

RESEARCH AREAS

[Cancer Biology Research](#)

[Cancer Genomics Research](#)

[Research on Causes of Cancer](#)

[Cancer Diagnosis Research](#)

[Cancer Prevention Research](#)

[Screening & Early Detection](#)

Cancer Treatment Research

[Cancer & Public Health](#)

[Cancer Health Disparities](#)

[Childhood Cancers Research](#) +

[Clinical Trials Research](#) +

[Global Cancer Research](#)

NCI and the Precision Medicine Initiative®

The Precision Medicine Initiative® (PMI) is a \$215 million investment in the National Institutes of Health's (NIH) fiscal year 2016 budget to accelerate biomedical research and provide clinicians with new tools to select the therapies that can be used in a more individualized approach with patients. NCI is using \$70 million of that investment to advance the field of precision oncology. Other disease areas will be considered by NIH over the longer term.

Oncology is a natural choice as the initial focus for this ambitious initiative. Precision medicine uses the genetics of disease to identify effective therapies, and, thanks in large part to NCI-supported research, we know that cancer is a disease of the genome.

NCI has been on the forefront of precision medicine since 2014. The institute has launched a series of precision medicine clinical trials and, as a result, many [genetically targeted therapies](#) are currently available to cancer patients

NATIONAL CANCER INSTITUTE

PRECISION MEDICINE IN CANCER TREATMENT

Discovering unique therapies that treat an individual's cancer based on the specific genetic abnormalities of that person's tumor.



VIEW INFOGRAPHIC >

ImmunoMATCH Details

- Master chaired by Drs. Ken Grossman and Katerina Politi
 - SWOG portfolio: Dr. Siwen Hu-Lieskovan
- Variety of eligible solid tumors
- First- and second-line therapies
- Emphasis on combinations
- Launching in 2020

SWOG Latin America Initiative

5 NCI studies close to activation



- S1802
- S1714
- S1827
- BR003
- InPACT

July 29 Plain Language Workshop



Plain Language in the NCTN

- No group currently employs a plain language writer
- Printable/shareable trial summaries posted on SWOG.org
- Our thanks to The Hope Foundation for Cancer Research

Community Advocate Program

- Brings a new “style” of advocate to SWOG
- Representation from those with a different perspective
- Helps with diversity of trial participants, including accrual tactics in special populations

Community Advocates



30 Years of Leading SWOG!



Farewells & Welcomes

Outgoing ORP Chair



Keisha Humphries, RN, BSN, OCN

Incoming ORP Chair



Connie Szczepanek, RN, BSN, CCRP

Incoming Melanoma Chair



Kenneth Grossmann, MD

Incoming Immunotherapy Co-Chair



Siwen Hu-Lieskovan, MD, PhD

THE **HOPE**
FOUNDATION
FOR CANCER RESEARCH

SUPPORTING SWOG CANCER RESEARCH NETWORK

2019 Young Investigators



2019 SWOG Young Investigators

Arya Amini, MD

City of Hope

Jose Rodrigo Espinosa Fernandez, MD

Instit. Nacional de Cancerologia

Leah Ferrucci, PhD, MPH

Yale School of Public Health

Brian Hess, MD

Medical Univ. of South Carolina

Benjamin Maughan, MD, PharmD

Huntsman Cancer Institute

Jing (Christine) Ye, MD

University of Michigan

2019 SEED Award

Dan L. Hertz, PharmD, PhD
University of Michigan College of Pharmacy

Siu-Fun Wong, PharmD
Chapman University

**“Prospective Drug-Drug Interaction Screening in
SWOG Clinical Trials”**

Plenary Speaker



Don Dizon, MD

Plenary Speaker



Mark Lewis, MD

Plenary Speaker



Bonnie Spring, PhD

Harry Hynes Memorial Lecturer



Olufunmilayo Olopade, MD











